<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10188899</article-id><article-id pub-id-type="pmc">2362739</article-id><article-id pub-id-type="pii">6690241</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690241</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Boer</surname><given-names>R H de</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>I E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pastorino</surname><given-names>U</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>O'Brien</surname><given-names>M E R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ramage</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ashley</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Goldstraw</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><aff id="aff1">Department of Medicine, Royal Marsden NHS Trust, Fulham Rd, London, SW3 6JJ, UK</aff><aff id="aff2">Department of Thoracic Surgery, Royal Brompton Hospital, Sydney St, London, SW3 6JJ, UK</aff></contrib-group><pub-date pub-type="ppub"><month>3</month><year>1999</year></pub-date><volume>79</volume><issue>9-10</issue><fpage>1514</fpage><lpage>1518</lpage><history><date date-type="received"><day>26</day><month>06</month><year>1998</year></date><date date-type="rev-recd"><day>28</day><month>08</month><year>1998</year></date><date date-type="accepted"><day>07</day><month>10</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Surgical resection offers the best chance for cure for early stage non-small-cell lung cancer (NSCLC, stage I, II, IIIA), but the 5-year survival rates are only moderate, with systemic relapse being the major cause of death. Pre-operative (neo-adjuvant) chemotherapy has shown promise in small trials restricted to stage IIIA patients. We believe similar trials are now appropriate in all stages of operable lung cancer. A feasibility study was performed in 22 patients with early stage (IB, II, IIIA) resectable NSCLC; randomized to either three cycles of chemotherapy [mitomycin-C 8 mg m<sup>&#x02212;2</sup>, vinblastine 6 mg m<sup>&#x02212;2</sup> and cisplatin 50 mg m<sup>&#x02212;2</sup> (MVP)] followed by surgery (<italic>n</italic> = 11), or to surgery alone. Of 40 eligible patients, 22 agreed to participate (feasibility 55&#x00025;) and all complied with the full treatment schedule. All symptomatic patients achieved either complete (50&#x00025;) or partial (50&#x00025;) relief of tumour-related symptoms with pre-operative chemotherapy. Fifty-five per cent achieved objective tumour response, and a further 27&#x00025; minor tumour shrinkage; none had progressive disease. Partial pathological response was seen in 50&#x00025;. No severe (WHO grade III&#x02013;IV) toxicities occurred. No significant deterioration in quality of life was detected during chemotherapy. Pre-operative MVP chemotherapy is feasible in early stage NSCLC, and this study has now been initiated as a UK-wide Medical Research Council phase III trial. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>non-small-cell lung cancer</kwd><kwd>pre-operative chemotherapy</kwd><kwd>mitomycin-C</kwd><kwd>vinblastine</kwd><kwd>cisplatin</kwd></kwd-group></article-meta></front></article>
